Brought to you by 
Zurex brings in $6.2mm in first close of Series C
16 Aug 2016
Executive Summary
Zurex Pharma Inc., a developer of antimicrobial products to prevent hospital-acquired infections, raised $6.2mm in the initial close of its Series C financing to new and existing shareholders. According to the Form D, 26 investors participated and the round could reach $8mm. The company will use the proceeds for Phase III trials of lead compound ZuraPrep to help prevent surgical site infections.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zurex brings in $6.2mm in first close of Series C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice